Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Joline S.J. Lim et al.|Cancer Discovery|2020Cited by 134
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119